Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LELAND N ALLEN

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1245258573
CMS profile
55913
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$368.99

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $212.01 11
Education $156.98 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LELAND N ALLEN

NPI 1245258573 · CMS profile ID 55913

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245258573?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LELAND N ALLEN, NPI 1245258573, CMS profile ID 55913. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245258573?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LELAND N ALLEN, NPI 1245258573, CMS profile ID 55913. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245258573?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LELAND N ALLEN, NPI 1245258573, CMS profile ID 55913, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1245258573?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $368.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $15.1312/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141625745 CMS
La Jolla Pharmaceutical Company $15.7711/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154246916 CMS
Paratek Pharmaceuticals, Inc. $15.2210/02/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1113890448 CMS
La Jolla Pharmaceutical Company $25.8309/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154246914 CMS
Melinta Therapeutics, LLC $21.5108/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140483190 CMS
La Jolla Pharmaceutical Company $14.9208/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154246912 CMS
La Jolla Pharmaceutical Company $23.1006/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154246910 CMS
Novo Nordisk Inc $15.9506/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097803004 CMS
La Jolla Pharmaceutical Company $15.3504/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154246908 CMS
AstraZeneca Pharmaceuticals LP $32.1801/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105899440 CMS
Astellas Pharma US Inc $17.0501/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139290480 CMS
Astellas Pharma US Inc $76.9901/18/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139388352 CMS
Astellas Pharma US Inc $79.9901/18/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139388354 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,146.19 68
PY2020 $344.62 27
PY2021 $468.66 29
PY2022 $127.11 7
PY2023 $45.03 3
PY2024 $368.99 13
PY2025 $356.74 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $394,977.43 20
PY2023 Principal investigator $532,033.34 44
PY2022 Principal investigator $2,884,761.18 187
PY2021 Principal investigator $4,662,082.09 207

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

207 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $227.65 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947673
Principal investigator 2 ModernaTX, Inc. $942.64 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947705
Principal investigator 1 ModernaTX, Inc. $1,828.21 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947733
Principal investigator 2 ModernaTX, Inc. $1,828.21 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947735
Principal investigator 1 ModernaTX, Inc. $1,828.21 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947737
Principal investigator 2 ModernaTX, Inc. $3,360.15 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947749
Principal investigator 2 ModernaTX, Inc. $6,829.46 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947759
Principal investigator 1 ModernaTX, Inc. $7,285.26 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947761
Principal investigator 1 ModernaTX, Inc. $8,100.00 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947765
Principal investigator 2 ModernaTX, Inc. $8,154.00 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947767
Principal investigator 2 ModernaTX, Inc. $11,382.43 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947777
Principal investigator 1 ModernaTX, Inc. $12,382.78 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947785
Principal investigator 2 ModernaTX, Inc. $12,595.50 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947787
Principal investigator 1 ModernaTX, Inc. $12,696.75 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947789
Principal investigator 2 ModernaTX, Inc. $15,336.00 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947801
Principal investigator 2 ModernaTX, Inc. $16,254.00 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947805
Principal investigator 2 ModernaTX, Inc. $20,358.00 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947823
Principal investigator 1 ModernaTX, Inc. $22,173.75 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947827
Principal investigator 1 ModernaTX, Inc. $23,228.06 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947831
Principal investigator 2 ModernaTX, Inc. $24,563.25 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947837
Principal investigator 2 ModernaTX, Inc. $26,899.87 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947847
Principal investigator 2 ModernaTX, Inc. $32,839.06 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947851
Principal investigator 2 ModernaTX, Inc. $39,578.76 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947857
Principal investigator 1 ModernaTX, Inc. $504,324.90 12/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947865
Principal investigator 1 ModernaTX, Inc. $346.28 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947679
Principal investigator 2 ModernaTX, Inc. $692.55 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947695
Principal investigator 1 ModernaTX, Inc. $865.69 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947701
Principal investigator 1 ModernaTX, Inc. $1,038.83 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947709
Principal investigator 1 ModernaTX, Inc. $1,304.30 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947723
Principal investigator 2 ModernaTX, Inc. $1,385.10 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947727
Principal investigator 1 ModernaTX, Inc. $1,558.24 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947729
Principal investigator 1 ModernaTX, Inc. $1,680.08 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947731
Principal investigator 2 ModernaTX, Inc. $2,597.06 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947745
Principal investigator 1 ModernaTX, Inc. $2,770.20 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947747
Principal investigator 2 ModernaTX, Inc. $7,825.82 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947763
Principal investigator 2 ModernaTX, Inc. $13,043.03 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947791
Principal investigator 1 ModernaTX, Inc. $16,794.34 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947811
Principal investigator 1 ModernaTX, Inc. $19,045.13 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947817
Principal investigator 2 ModernaTX, Inc. $21,122.78 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947825
Principal investigator 2 ModernaTX, Inc. $23,521.05 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947833
Principal investigator 1 ModernaTX, Inc. $55,442.47 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947859
Principal investigator 2 ModernaTX, Inc. $168,255.02 12/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947863
Principal investigator 1 PFIZER INC. $28,908.24 12/22/2021 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832564357
Principal investigator 1 ModernaTX, Inc. $1,924.43 12/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947739
Principal investigator 2 ModernaTX, Inc. $37,938.45 12/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947855
Principal investigator 1 ModernaTX, Inc. $1,000.35 12/10/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947707
Principal investigator 2 ModernaTX, Inc. $2,000.70 12/10/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947743
Principal investigator 2 ModernaTX, Inc. $10,173.44 12/10/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947775
Principal investigator 1 ModernaTX, Inc. $14,947.54 12/10/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947795
Principal investigator 2 ModernaTX, Inc. $15,005.25 12/10/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947797
Principal investigator 2 ModernaTX, Inc. $15,005.25 12/10/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947799
Principal investigator 1 PFIZER INC. $9,339.84 12/07/2021 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832564743
Principal investigator 1 ModernaTX, Inc. $256.50 11/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947675
Principal investigator 1 ModernaTX, Inc. $10,141.39 11/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947773
Principal investigator 1 ModernaTX, Inc. $15,515.58 11/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947803
Principal investigator 1 ModernaTX, Inc. $17,371.49 11/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947813
Principal investigator 1 ModernaTX, Inc. $19,006.65 11/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947815
Principal investigator 2 ModernaTX, Inc. $24,008.40 11/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947835
Principal investigator 2 ModernaTX, Inc. $26,048.30 11/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947843
Principal investigator 2 ModernaTX, Inc. $26,236.75 11/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947845
Principal investigator 1 PFIZER INC. $11,674.80 11/23/2021 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832672143
Principal investigator 1 Gilead Sciences, Inc. $508.00 11/17/2021 Non-covered Recipient Entity
ST VINCENTS HEALTH SYSTEM
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 803515259
Principal investigator 2 ModernaTX, Inc. $350.00 11/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947681
Principal investigator 2 ModernaTX, Inc. $75.00 11/12/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947671
Principal investigator 1 ModernaTX, Inc. $1,050.00 11/12/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947711
Principal investigator 1 ModernaTX, Inc. $4,415.86 11/10/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947751
Principal investigator 2 ModernaTX, Inc. $75.00 11/05/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947669
Principal investigator 2 ModernaTX, Inc. $513.00 11/05/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947687
Principal investigator 1 ModernaTX, Inc. $1,200.00 11/05/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947719
Principal investigator 1 ModernaTX, Inc. $20,113.69 11/05/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947821
Principal investigator 2 ModernaTX, Inc. $455.30 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947683
Principal investigator 1 ModernaTX, Inc. $682.95 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947693
Principal investigator 1 ModernaTX, Inc. $1,146.60 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947715
Principal investigator 1 ModernaTX, Inc. $1,289.56 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947721
Principal investigator 1 ModernaTX, Inc. $8,208.00 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947769
Principal investigator 2 ModernaTX, Inc. $8,262.00 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947771
Principal investigator 1 ModernaTX, Inc. $11,907.00 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947779
Principal investigator 1 ModernaTX, Inc. $12,155.13 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947781
Principal investigator 1 ModernaTX, Inc. $12,352.50 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947783
Principal investigator 2 ModernaTX, Inc. $13,645.88 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947793
Principal investigator 1 ModernaTX, Inc. $16,362.00 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947807
Principal investigator 2 ModernaTX, Inc. $16,524.00 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947809
Principal investigator 1 ModernaTX, Inc. $19,109.44 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947819
Principal investigator 2 ModernaTX, Inc. $23,044.50 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947829
Principal investigator 1 ModernaTX, Inc. $24,745.50 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947839
Principal investigator 2 ModernaTX, Inc. $25,496.63 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947841
Principal investigator 1 ModernaTX, Inc. $32,245.37 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947849
Principal investigator 1 ModernaTX, Inc. $35,605.44 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947853
Principal investigator 2 ModernaTX, Inc. $92,769.80 10/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947861
Principal investigator 1 Gilead Sciences, Inc. $9,823.00 10/20/2021 Non-covered Recipient Entity
ST VINCENTS HEALTH SYSTEM
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 803515257
Principal investigator 2 ModernaTX, Inc. $43.88 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947667
Principal investigator 1 ModernaTX, Inc. $263.28 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947677
Principal investigator 1 ModernaTX, Inc. $500.00 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947685
Principal investigator 2 ModernaTX, Inc. $600.00 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947689
Principal investigator 2 ModernaTX, Inc. $710.00 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947697
Principal investigator 1 ModernaTX, Inc. $850.00 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947699
Principal investigator 1 ModernaTX, Inc. $1,097.00 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947713
Principal investigator 1 ModernaTX, Inc. $1,200.00 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947717
Principal investigator 2 ModernaTX, Inc. $1,360.28 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947725
Principal investigator 1 ModernaTX, Inc. $1,950.00 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947741
Principal investigator 2 ModernaTX, Inc. $5,000.00 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947753
Principal investigator 1 ModernaTX, Inc. $5,530.29 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947755
Principal investigator 2 ModernaTX, Inc. $5,825.00 10/06/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947757
Principal investigator 1 ModernaTX, Inc. $600.00 10/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947691
Principal investigator 2 ModernaTX, Inc. $940.00 10/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860947703
Principal investigator 2 Moderna TX, Inc. $384.75 09/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336895
Principal investigator 1 Moderna TX, Inc. $22,309.55 09/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337475
Principal investigator 1 Moderna TX, Inc. $25,496.63 09/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337519
Principal investigator 1 Moderna TX, Inc. $1,107.00 09/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337625
Principal investigator 2 Moderna TX, Inc. $22,764.85 09/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337747
Principal investigator 1 Moderna TX, Inc. $227.65 09/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337821
Principal investigator 1 Moderna TX, Inc. $6,374.16 09/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337877
Principal investigator 1 Moderna TX, Inc. $384.75 09/24/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337893
Principal investigator 1 Gilead Sciences, Inc. $16,695.00 09/22/2021 Non-covered Recipient Entity
ST VINCENTS HEALTH SYSTEM
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 803515255
Principal investigator 2 Moderna TX, Inc. $16,686.00 09/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336915
Principal investigator 2 Moderna TX, Inc. $25,332.75 09/22/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336921
Principal investigator 1 PFIZER INC. $11,320.00 09/22/2021 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832672153
Principal investigator 2 Moderna TX, Inc. $1,107.00 09/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336857
Principal investigator 1 Moderna TX, Inc. $20,716.01 09/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336909
Principal investigator 2 Moderna TX, Inc. $3,993.92 09/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336927
Principal investigator 1 Moderna TX, Inc. $4,787.64 09/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336933
Principal investigator 1 Moderna TX, Inc. $455.30 09/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337423
Principal investigator 2 Moderna TX, Inc. $8,154.00 09/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337449
Principal investigator 1 Moderna TX, Inc. $12,129.75 09/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337539
Principal investigator 1 Moderna TX, Inc. $12,639.27 09/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337679
Principal investigator 1 Moderna TX, Inc. $17,073.64 09/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337741
Principal investigator 2 Moderna TX, Inc. $6,703.84 09/17/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337799
Principal investigator 2 Moderna TX, Inc. $600.00 09/15/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337579
Principal investigator 1 Moderna TX, Inc. $5,755.00 09/15/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337787
Principal investigator 2 Moderna TX, Inc. $240.00 09/15/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337803
Principal investigator 1 Moderna TX, Inc. $4,395.30 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336889
Principal investigator 1 Moderna TX, Inc. $20,716.01 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337405
Principal investigator 2 Moderna TX, Inc. $24,137.76 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337411
Principal investigator 2 Moderna TX, Inc. $10,099.63 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337457
Principal investigator 2 Moderna TX, Inc. $2,093.00 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337483
Principal investigator 2 Moderna TX, Inc. $2,276.49 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337507
Principal investigator 1 Moderna TX, Inc. $22,764.85 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337525
Principal investigator 2 Moderna TX, Inc. $8,669.28 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337595
Principal investigator 2 Moderna TX, Inc. $7,740.05 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337633
Principal investigator 2 Moderna TX, Inc. $16,902.00 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337669
Principal investigator 1 Moderna TX, Inc. $682.95 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337689
Principal investigator 2 Moderna TX, Inc. $5,830.50 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337729
Principal investigator 1 Moderna TX, Inc. $1,315.60 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337735
Principal investigator 1 Moderna TX, Inc. $227.65 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337793
Principal investigator 1 Moderna TX, Inc. $1,917.91 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337837
Principal investigator 2 Moderna TX, Inc. $2,527.17 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337843
Principal investigator 1 Moderna TX, Inc. $4,425.92 09/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337889
Principal investigator 2 Moderna TX, Inc. $8,100.00 08/27/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337861
Principal investigator 1 Moderna TX, Inc. $1,625.58 08/25/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337469
Principal investigator 2 Moderna TX, Inc. $455.30 08/25/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337607
Principal investigator 1 Moderna TX, Inc. $227.65 08/25/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337715
Principal investigator 1 Moderna TX, Inc. $455.30 08/25/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337722
Principal investigator 2 Moderna TX, Inc. $2,427.14 08/25/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337773
Principal investigator 2 Moderna TX, Inc. $11,603.25 08/18/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337501
Principal investigator 2 Moderna TX, Inc. $4,565.00 08/18/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337543
Principal investigator 1 Moderna TX, Inc. $23,712.75 08/18/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337809
Principal investigator 2 Moderna TX, Inc. $7,015.00 08/18/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337905
Principal investigator 2 Moderna TX, Inc. $1,289.56 08/02/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337437
Principal investigator 2 Moderna TX, Inc. $682.95 08/02/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337489
Principal investigator 2 Moderna TX, Inc. $1,828.21 08/02/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337815
Principal investigator 1 Moderna TX, Inc. $38,934.91 08/02/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337827
Principal investigator 2 Moderna TX, Inc. $1,397.93 08/02/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337909
Principal investigator 1 Moderna TX, Inc. $227.65 08/02/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337921
Principal investigator 1 Gilead Sciences, Inc. $18,200.00 07/26/2021 Non-covered Recipient Entity
ST VINCENTS HEALTH SYSTEM
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 803515253
Principal investigator 1 Moderna TX, Inc. $99,792.62 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337463
Principal investigator 2 Moderna TX, Inc. $128,752.08 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337513
Principal investigator 1 Moderna TX, Inc. $196,345.34 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337551
Principal investigator 1 Moderna TX, Inc. $2,049.44 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337561
Principal investigator 2 Moderna TX, Inc. $125,145.61 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337573
Principal investigator 2 Moderna TX, Inc. $127,573.82 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337601
Principal investigator 1 Moderna TX, Inc. $33,780.35 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337619
Principal investigator 2 Moderna TX, Inc. $47,198.30 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337645
Principal investigator 1 Moderna TX, Inc. $52,855.31 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337659
Principal investigator 1 Moderna TX, Inc. $106,212.65 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337663
Principal investigator 2 Moderna TX, Inc. $58,560.95 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337673
Principal investigator 2 Moderna TX, Inc. $64,143.80 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337703
Principal investigator 2 Moderna TX, Inc. $53,141.96 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337779
Principal investigator 2 Moderna TX, Inc. $8,063.74 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337849
Principal investigator 2 Moderna TX, Inc. $153,545.70 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337867
Principal investigator 1 Moderna TX, Inc. $91,571.80 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337899
Principal investigator 2 Moderna TX, Inc. $41,805.10 07/21/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337915
Principal investigator 2 Moderna TX, Inc. $103,424.43 07/14/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337419
Principal investigator 2 Moderna TX, Inc. $28,715.75 07/14/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337533
Principal investigator 1 Moderna TX, Inc. $45,756.68 07/09/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336873
Principal investigator 1 Moderna TX, Inc. $152,138.36 07/09/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337495
Principal investigator 2 Moderna TX, Inc. $146,433.63 07/09/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337613
Principal investigator 2 Moderna TX, Inc. $36,291.64 07/09/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337639
Principal investigator 2 Moderna TX, Inc. $126,843.64 07/09/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337651
Principal investigator 1 Moderna TX, Inc. $23,694.58 07/09/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337761
Principal investigator 2 Moderna TX, Inc. $8,262.00 07/07/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337443
Principal investigator 2 Moderna TX, Inc. $7,722.00 07/07/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337873
Principal investigator 2 Moderna TX, Inc. $11,502.00 07/02/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337567
Principal investigator 2 Moderna TX, Inc. $13,243.50 07/02/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337685
Principal investigator 2 Moderna TX, Inc. $25,818.75 07/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337585
Principal investigator 2 Moderna TX, Inc. $14,904.00 07/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337709
Principal investigator 2 Moderna TX, Inc. $23,044.50 07/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337753
Principal investigator 2 Moderna TX, Inc. $16,578.00 07/01/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337883
Principal investigator 2 Moderna TX, Inc. $60,902.74 06/25/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337431
Principal investigator 2 Moderna TX, Inc. $3,725.00 06/25/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337589
Principal investigator 2 Moderna TX, Inc. $600.00 06/25/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337767
Principal investigator 2 Moderna TX, Inc. $1,144.64 06/25/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337833
Principal investigator 1 Moderna TX, Inc. $24,883.44 06/23/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336867
Principal investigator 2 Moderna TX, Inc. $12,081.15 06/23/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336883
Principal investigator 2 Moderna TX, Inc. $3,642.38 06/23/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806336901
Principal investigator 1 Moderna TX, Inc. $1,865.40 06/23/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337555
Principal investigator 2 Moderna TX, Inc. $10,637.19 06/23/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337697
Principal investigator 2 Moderna TX, Inc. $3,390.31 06/23/2021 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806337855